Key facts: GSK Buyback Reaches 237M Shares; CDC Talks Impact Vaccines
On December 4, 2025, GSK plc bought 11,764,733 shares in its buyback program, raising total treasury shares to 237,229,577, which is 5.82% of voting rights.1GSK, with Merck, makes hepatitis B vaccines. Recent CDC ACIP talks on vaccination schedules could impact GSK's vaccine supply and distribution.2